Brandes Investment Partners Adds $35M in Sanofi ($SNY)

Brandes Investment Partners has made a significant move by boosting its stake in Sanofi, traded as SNY on the NasdaqGS. According to a recent 13F filing with the SEC, the firm increased its holdings by 27.8% during the reporting period, adding 809,844 shares. This brings its total to 3,723,100 shares, valued at approximately $164.7 million.

What Changed in Brandes Investment Partners' Sanofi Position

Brandes Investment Partners added 809,844 shares of Sanofi, raising its stake by 27.8% to a total of 3,723,100 shares. Prior to this increase, the firm held 2,913,256 shares. This adjustment reflects a strategic decision to deepen its investment in the healthcare company.

Other Institutional Activity in Sanofi

Several other institutional investors also adjusted their positions in Sanofi. Dodge & Cox reduced its holdings by 26,987,967 shares, ending with 29,504,632 shares valued at about $1.42 billion. In contrast, Morgan Stanley increased its stake by 3,409,671 shares, bringing its total to 12,511,867 shares worth approximately $602.8 million. Fisher Asset Management trimmed its position by 698,452 shares, now holding 11,442,163 shares valued at $551.3 million. Bank of America Corp added 940,342 shares, totaling 9,484,350 shares valued at $457 million. Meanwhile, Franklin Resources increased its holdings by 2,065,096 shares to 7,165,193 shares worth $345.2 million.

Sanofi Stock Snapshot

Shares of Sanofi, listed as SNY on the NasdaqGS, recently traded at $44.25. The company boasts a market capitalization of approximately $105.9 billion. Sanofi's P/E ratio stands at 19.41, with a forward P/E of 8.37. The stock's beta is 0.275, indicating lower volatility compared to the market. Over the past year, the stock's price ranged from a low of $42.28 to a high of $52.68. Currently, Sanofi's 50-day moving average is $45.09, while its 200-day moving average is $47.28.

Recent Earnings

Sanofi reported revenues of $47.35 billion with a growth rate of 6%. The company achieved an earnings per share (EPS) of $2.28. Its net margin stands at 15.95%, and return on equity (ROE) is 6.58%. Sanofi plans to release its next earnings report on July 30, 2026.

Dividend

Sanofi offers an annual dividend rate of $2.42 per share, yielding 5.47% based on current prices. The company's dividend payout ratio is high at 97.73%, reflecting a commitment to returning profits to shareholders.

Analysts Set New Price Targets

Morgan Stanley upgraded Sanofi to a buy rating on September 8, 2025, with a price target of $58. Goldman Sachs initiated coverage with a hold rating and a $65 target on March 21, 2025. Argus Research has consistently maintained a buy rating, with the latest target set at $60 on July 26, 2024. Analysts have a consensus buy recommendation with a mean price target of $55.9 across nine opinions.

About Sanofi

Sanofi, headquartered in Paris, France, operates in the healthcare sector, specifically in the drug manufacturing industry. The company is involved in the research, development, and marketing of therapeutic solutions, including vaccines and treatments for various diseases. Led by CEO Ms. Belen Garijo Lopez, Sanofi employs approximately 74,846 people worldwide.

Bottom Line

Brandes Investment Partners' decision to significantly increase its stake in Sanofi suggests confidence in the company's future. While this 13F filing reflects positions as of the reporting period and may not indicate current holdings, it provides insight into institutional sentiment. Investors often track such filings to gauge market trends and institutional confidence.